Can Alkermes' Vivitrol Live Up To Commercial Potential In Opioid Dependence?
This article was originally published in The Pink Sheet Daily
Executive Summary
Company does not plan to compete against market-leading Suboxone, and will initially target the newly addicted, such as young adults, and certain professionals who can't take available treatments.